Efficacy of Rifaximin With NAC in IBS-D | MicrobiomeTrials← Back to trialsNCT06727422
Efficacy of Rifaximin With NAC in IBS-D
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-02-04Est. Completion: 2026-08-01
Enrollment target: 225 participants Locations- Cedars-Sinai Medical Center, Los Angeles, California, United States
Other microbiome trials you might be interested in
Functional Gastrointestinal Disorders (FGID)
Brief Summary
Functional gastrointestinal disorders (FGID), including irritable bowel syndrome (IBS), are common condit…
Multiple LocationsEst. completion Sep 1, 2027
Irritable Bowel Syndrome (IBS)
To explore the efficacy of pregabalin for patients with irritable bowel syndrome (IBS).
Beijing, ChinaEst. completion Apr 8, 2026
Ulcerative Colitis
Healthy
Irritable Bowel Syndrome With Diarrhea
This trial is being completed to learn about how Aquamin® affects gastrointestinal permeability, or the control of mater…
Ann Arbor, United StatesCompleted Mar 11, 2024